Voy­ager shares take a hit as FDA slaps a hold on the IND for Hunt­ing­ton's gene ther­a­py — their #2 play in the pipeline

A lit­tle more than a year af­ter Sanofi hand­ed back rights to Voy­ager’s $VY­GR gene ther­a­py pro­gram for Hunt­ing­ton’s in ex­change for a cash pay­ment, the biotech says the FDA has placed a hold on the IND need­ed to get in­to the clin­ic.

The word from Voy­ager — the FDA re­mains mute in these cas­es — is that the hold on VY-HTT01 deals with CMC is­sues, some­thing that typ­i­cal­ly isn’t the kiss of death for a biotech com­pa­ny. But it will put the brakes on things for an un­cer­tain pe­ri­od of time for Voy­ager, now helmed by An­dre Turenne.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters